Login to Your Account



Renamed Adheron cements focus on Cadherin-11 asset

By Jennifer Boggs
Managing Editor

Friday, December 27, 2013
Back in 2006, a company named Synovex Corp. was launched around discoveries by scientists Michael Brenner and David Lee into the role of Cadherin-11 as an adhesive control part of cell-cell interaction. And for several years, the fully virtual discovery firm operated under the radar until a lead clinical asset emerged: an antibody designed to inhibit Cad-11 designated SDP051.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription